Publications by authors named "F Onen"
CT-P13 is a biosimilar version of infliximab, a monoclonal antibody. In individuals with ankylosing spondylitis (AS), CT-P13 has been shown to be effective and to have a well-tolerated safety profile. The aim of this study was to evaluate the long-term drug persistence, safety, and efficacy of infliximab biosimilar CT-P13 in patients with AS undergoing first-line (1st-line) and later (≥2nd-line) treatment in clinical practice.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to evaluate the retention rates and remission outcomes of patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who started treatment with secukinumab over 24 and 48 months.
- Data was collected from 13 European registries, revealing that retention rates were around 51%-64%, and patients with no prior biologic treatments showed better outcomes compared to those with previous treatments.
- The findings suggest that secukinumab remains effective over four years, with higher success rates in treatment-naïve patients compared to those who had already tried other therapies.
Article Synopsis
- The study investigates the north-south gradient hypothesis, suggesting that individuals with rheumatoid arthritis (RA) in southern regions (like Turkey) tend to have a younger age of onset and milder disease than those in northern regions (like Denmark).
- In a comparison of 223 treatment-naïve RA patients from Denmark and Turkey, it was found that Danish patients had a later onset age (60 years) and more severe joint symptoms compared to Turkish patients (51 years).
- The findings support the hypothesis and reveal that Danish patients have more genetic risk factors for RA, prompting the need for future research into the genetic and environmental influences on these regional differences.
Article Synopsis
- The study aimed to explore gender differences in the phenotypical expression of Behçet's disease (BD) using data from the International AIDA Network Registry, focusing on damage index, disease manifestations, and cardiovascular risk.
- A total of 1024 patients (567 males and 457 females) were examined, revealing that males had a significantly higher overall damage index and more frequent occurrences of uveitis and vascular involvement, while females showed higher instances of arthralgia, arthritis, and CNS involvement.
- Key factors associated with major organ involvement included male gender, treatment with biologic agents, origin from endemic regions, and longer disease duration, indicating a more severe course of BD in males compared to females.
Fabry disease in familial Mediterranean fever according to the severity of the disease.
Reumatol Clin (Engl Ed)
November 2024
Objectives: Mutations in the α-galactosidase A (GLA) gene result in Fabry disease (FD), a rare metabolic condition. FD patients present with heterogeneous clinical manifestations, which may overlap with systemic diseases including familial Mediterranean fever (FMF). The aim of this study was to determine the frequency of FD in patients with mild and severe FMF and to prevent misdiagnosis by increasing clinicians' awareness.
View Article and Find Full Text PDF